Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR
   

/by

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR
   

/by

25 years of expanding access to cancer care

25 years of expanding access to cancer care
tavasat1

/by

25 years of expanding access to cancer care

25 years of expanding access to cancer care
tavasat1

/by

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis

  • Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goals
  • New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab in patients with atrial fibrillation, including recurrent bleeding events
  • Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice
/by

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
arcticnovartis

  • Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population

  • PSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in combination with standard of care (ADT + ARPI) vs. SoC alone, with positive overall survival trend (HR=0.80)

  • mHSPC is incurable and about half of men progress within 20 months, highlighting need for differentiated, precision approaches earlier in disease journey
/by

Smarter decisions at scale: How Novartis is using AI to advance R&D

Smarter decisions at scale: How Novartis is using AI to advance R&D
halesmi2

/by